Bladder cancer model could pave the way for better drug efficacy studies

May 21, 2018

CHAPEL HILL - Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients respond to new immune-based treatments.

In the journal Cancer Research, UNC Lineberger's William Y. Kim, MD, Benjamin G. Vincent, MD, and colleagues report they have developed a mouse model of luminal bladder cancer, one of the two subtypes of advanced bladder cancer. The researchers said this model may help them to determine which patients may respond to checkpoint inhibitors, a class of immunotherapy drugs that "remove the brakes" that can keep the immune system from attacking cancer cells.

Five checkpoint inhibitors have been approved for metastatic, or locally advanced, bladder cancer since May 2016, giving patients additional options after standard therapy failed. But studies have shown that less than a quarter of patients will respond to these drugs.

"Not all bladder cancers are the same, and until now, we didn't have the tools to understand biology or look at the therapeutic efficacy of drugs in luminal preclinical models," said Kim, who is an associate professor in the UNC School of Medicine Departments of Genetics, Pharmacology, and Urology. "The biggest impact is that the scientific community now has a mouse model that can be used to understand the biology of these bladder tumors better, and to evaluate promising therapies."

The researchers used their newly created model and an existing model for basal-like bladder cancer, the other subtype of bladder cancer, to examine features that may determine the effectiveness of checkpoint inhibitors.

They studied the immune microenvironment - the immune cells in and around the tumor -- for each subtype. They determined there was lower levels of immune cells in and around luminal tumors, and that this model did not respond as well to PD-1 inhibitors.

They also analyzed the level of neo-antigens present on the two different bladder cancer subtypes. Neoantigens are proteins that sprout on the surface of cancer tumors as a result of DNA mutations or other alternations in cancer cells. Scientists are interested in using neoantigens to predict response to immunotherapy treatments, or as drug targets.

"We think neoantigens are at least a large reason for why there is an anti-tumor immune response - meaning the body uses the neo-antigens to recognize the tumor as foreign," Kim said. "There's a lot of interest in trying to leverage neo-antigens therapeutically, and so we wanted to see if our model expressed them."

Vincent's lab used genetic sequencing to predict which abnormal proteins would appear on the surface of the cancer models, and then studied the extent to which the abnormal markers triggered the immune system. They found the luminal subtype had a lower number of markers that were highly immunogenic, or had the ability to trigger the immune system. "Understanding how and why tumors are differentially immunogenic is critical for understanding how to best use therapies that target the immune system in the clinic," Vincent said.

Kim said a future line of research will investigate how neo-antigens help to elicit an immune response, and whether they can leverage their findings to augment the activity of checkpoint inhibitors.

"The models will allow us to mechanistically understand why certain neo-antigens will cooperate with checkpoint inhibitors, and why others don't," Kim said.

Overall, he said the work could help to clarify the best approach for treating patients after their disease has progressed on the standard of care. It also provides a laboratory tool that accounts for bladder cancer being a disease with distinct subtypes.

"We are refining our understanding of cancers, and to make a parallel in another disease, I'd say to call breast cancer 'breast cancer' nowadays is not appropriate," Kim said "We call it HER2-positive breast cancer, or triple negative breast cancer, because these types are treated differently, and the biology underlying them is different. For bladder cancer, we now understand the same is true - that there are multiple subtypes of disease. We should no longer refer to bladder cancer as a single disease"
-end-
In addition to Kim and Vincent, the study's other authors include Ryoichi Saito, Christof C. Smith, Takanobu Utsumi, Lisa M. Bixby, Jordan Kardos, Sara E. Wobker, Kyle G. Stewart, Shengjie Chai, Ujjawal Manocha, Kevin M. Byrd, Jeffrey S. Damrauer, and Scott E. Williams.

The research was supported by the Bladder Cancer Advocacy Network Innovation Award and Young Investigator Award, the University Cancer Research Fund, the National Institutes of Health, and the UNC Oncology Clinical Translational Research Training Program.

UNC Lineberger Comprehensive Cancer Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.